Sam Brusco, Associate Editor05.26.22
Hologic has received CE marks for two new molecular assays, Panther Fusion EBV (Epstein-Barr virus) Quant Assay and Panther Fusion BKV (BK virus) Quant Assay. The assays quantify viral load of the respective viruses to help diagnose and manage solid organ and hematopoietic stem cell transplant patients.
The nucleic acid amplification tests (NAAT) run on Hologic’s automated Panther Fusion system and use real-time PCR technology. The EBV Quant assay can be used with whole blood and plasma samples; EKV Quant can be used with plasma and urine samples.
“Immunocompromised patients are vulnerable to a range of infections. As both the Epstein-Barr virus (EBV) and the BK virus (BKV) are extremely common and mainly asymptomatic, it is important that healthcare providers can quantitate and monitor for their presence,” Jan Verstreken, Group President, International at Hologic told the press. “These assays, along with our Aptima CMV Quant assay that we launched in Europe last year, provide our laboratory partners with the tools they need to accurately assess transplant patient samples quickly and confidently.”
“These two assays represent two firsts for us. They are the first quantitative assays developed for the Panther Fusion system, further expanding our existing portfolio of diagnostic and viral load tests. They are also the first Panther Fusion assays developed in our R&D facility in Liege, Belgium, which we acquired last year,” concluded Verstreken.
The nucleic acid amplification tests (NAAT) run on Hologic’s automated Panther Fusion system and use real-time PCR technology. The EBV Quant assay can be used with whole blood and plasma samples; EKV Quant can be used with plasma and urine samples.
“Immunocompromised patients are vulnerable to a range of infections. As both the Epstein-Barr virus (EBV) and the BK virus (BKV) are extremely common and mainly asymptomatic, it is important that healthcare providers can quantitate and monitor for their presence,” Jan Verstreken, Group President, International at Hologic told the press. “These assays, along with our Aptima CMV Quant assay that we launched in Europe last year, provide our laboratory partners with the tools they need to accurately assess transplant patient samples quickly and confidently.”
“These two assays represent two firsts for us. They are the first quantitative assays developed for the Panther Fusion system, further expanding our existing portfolio of diagnostic and viral load tests. They are also the first Panther Fusion assays developed in our R&D facility in Liege, Belgium, which we acquired last year,” concluded Verstreken.